Skip to content

13F-HR filed by Atlas Venture Life Science Advisors, LLC

Atlas Venture Life Science Advisors, LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-10 21:30:15 UTC, with 9 holding rows worth $631,189,317.

Accession
0001104659-26-125242
Filed
2026-11-10
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 9 entries on the cover page, a total value of $631,189,317 stated on the cover page (in dollars after the unit check, H1), rows summing to $631,189,317 with VALUE read as dollars as filed, 13F file number 028-22531. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
KYMERA THERAPEUTICS INC501575104COM2,847,541$318,326,608dollars as filed
DISC MEDICINE INC COM254604101Stock1,384,025$90,598,277dollars as filed
Obsidian Therapeutics, Inc.67448A106Common Stock, $0.0001 par value per share4,503,149$61,828,236dollars as filed
KAILERA THERAPEUTICS INC482931102COMMON STOCK5,171,282$59,056,040dollars as filed
DYNE THERAPEUTICS INC COM26818M108Stock3,440,720$55,429,999dollars as filed
Q32 BIO INC746964105Common Stock2,717,106$22,470,467dollars as filed
SIONNA THERAPEUTICS INC829401108COMMON STOCK2,995,602$15,756,867dollars as filed
KORRO BIO INC500946108COMMON STOCK773,260$7,663,007dollars as filed
Odyssey Therapeutics, Inc.67613T104COMMON STOCK2,692$59,816dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001104659-26-125242this filing2026-11-10